|
| |
AAOMS Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws
|
|
|
Bisphosphonate-related osteonecrosis of the jaw (BRON) adversely affects the quality of life and produces significant morbidity in afflicted patients. Oral and maxillofacial surgeons have been responsible for counseling, managing, and treating a majority of these patients. The strategies set forth in this position paper were developed by a Task Force appointed by the American Association of Oral and Maxillofacial Surgeons (AAOMS).
|
|
|
|
 |
|
|
| |
American Society for Bone and Mineral Research (ASBMR) Issues report on ONJ risk
|
|
|
The American Society for Bone and Mineral Research (ASBMR) announced today the publication of a report that examines the link between a class of widely prescribed drugs used to strengthen bones and the disorder known as Osteonecrosis of the Jaw (ONJ). The report, authored by an international, multidisciplinary task force, was convened by the ASBMR to look at the possible association between ONJ, a deterioration of the jawbone, and a class of drugs known as bisphosphonates, which in recent years have been linked to the condition.
|
|
|
|
|
|
|
| |
Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone.
|
|
An article from Cancer, in which researchers from the College of Dental Medicine, Nova Southeastern University in Fort Lauderdale, Florida present results of a study of 17 patients with cancer with bone metastases and 1 patient with osteopenia who received treatment with bisphosphonates and who subsequently developed osteonecrosis of the mandible and/or maxilla.
|
|
|
|
|
|
|
| |
Journal of the National Cancer Institute
|
|
|
Intravenous Bisphosphonate Therapy andInflammatory Conditions or Surgery of the Jaw: A Population-Based Analysis
|
|
|
|
|
|
|
| |
Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma
|
|
|
A multidisciplinary panel consisting of hematologists, dental specialists, and nurses specializing in the treatment of myeloma reviewed available data concerning the use of bisphosphonates. Guidelines for the use of bisphosphonates in MM were developed. This link is to the full article.
|
|
|
|
|
|
|
| |
NEJM Publishes Correspondence On ONJ
|
|
|
The New England Journal of Medicine published correspondence from Drs. Durie, Richardson, Duck and Tarassoff on Osteonecrosis of the Jaw in its July 7, 2005 issue (N Engl J Med. 2005 Jul 7;353(1):99-102; discussion 99-102.)
|
|
|
|
|
|
|
| |
Novartis and FDA notify dental healthcare professionals of revisions to the prescribing information
|
|
The prescribing information recommends that cancer patients receive a dental examination prior to initiating therapy with intravenous bisphosphonates and avoid invasive dental procedures while receiving bisphosphonate treatment.
|
|
|
|
|
|
|
| |
OSTEONECROSIS OF THE JAWS IN MYELOMA:
Time Dependent Correlation with AREDIA and ZOMETA Use
|
|
|
At the 2004 Annual Meeting of the American Society of Hematology, Dr. Durie presented the results of the web-based survey that many of you were kind enough to help us with. We are encouraged by the discussions that have ensued and are hopeful that this will help us raise awareness about this very serious issue and facilitate timely action.
|
|
|
|
|
|
|
| |
Osteonecrosis Web Survey Results Presented At 2004 ASH Meeting
|
|
|
|
|
|
| |
Special Advisory: Osteonecrosis of the Jaw
|
|
|
|
|
|
| |
Use of Bisphosphonates in Multiple Myeloma: IMWG Response to Mayo Clinic Consensus Statement
|
|
Published in the Mayo Clinic Proceedings 2007;82:516-522
|
|
|
|
|
|
|
| |
Wall Street Journal Article On Osteonecrosis Of The Jaws
|
|
|
You can also read a Wall Street Journal article that discusses this issue and includes a quote from Dr. Durie
|
|
|
|
|
|
|
| |
Aredia/Zometa and osteonecrosis of the jaws
|
|
|
|
|
|
| |
Food and Drug Administration (FDA) MedWatch Postings About Osteonecrosis Of The Jaw
|
|
|
FDA and Novartis notified healthcare professionals of revisions the PRECAUTIONS and ADVERSE REACTIONS sections of labeling for Aredia and Zometa
|
|
|
|
|
|
|
The committee discussed safety concerns, specifically osteonecrosis of the jaw (ONJ), associated with two bisphosphonates, NDA 21-223, ZOMETA® (zoledronic acid) Injection and AREDIA®, NDA 20-036 (pamidronate disodium for injection), both from Novartis Pharmaceuticals Corp. 
